A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of ...

The researchers found that both SGLT2 inhibitors and GLP-1 agonists were associated with a lower risk of major cardiovascular events, but the drug effects varied with the patients’ age.

Blockages in coronary arteries cause sudden heart attacks, leading to heart muscle damage. In contrast, heart failure is a ...

Experts are now calling for NHS guidance - which does not recommend managing diabetes with different drugs depending on age - ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

SGLT-2 inhibitors vs DPP-4 inhibitors were associated with a reduced risk for liver cirrhosis among patients with type 2 diabetes.

SGLT-2 inhibitors, compared with DPP-4 inhibitors ... To assess the effect of these drugs, compared with DPP-4 inhibitors, on the risk for cirrhosis and other severe liver complications ...

The study revealed a lower risk of nephrolithiasis with SGLT2 inhibitors than DPP4 inhibitors in both stone never-formers and ...

Discover how modern diabetes medications offer cardiovascular benefits, transforming diabetes care and improving outcomes worldwide.